Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns

Abstract

Estimates of the beta-interferon (IFNB) stopping rate in relapsing-remitting multiple sclerosis (RRMS) and secondary progressive MS (SPMS) vary and have been mainly derived from multicentre studies. This is a retrospective, hospital chart-based study of 394 patients treated by a single neurologist for up to eight years. The aims of the study were to ascertain the frequency and timing of IFNβ discontinuation in a well supported cohort, and to investigate whether the clinical disease type at the initiation of IFNβ or the reason for discontinuation influenced stopping rates. The median follow-up was 49 months. The overall IFNβ stopping rate was 28% over five years; there was a significant difference between the IFNβ stopping rates for RRMS (14%) and SPMS (23%) after three years of follow-up (P=0.0003). Patients stopped IFNβ due to side effects after a median of 13 months, and due to failure of therapy after a median of 35 months (P=0.0004). Significantly more patients with SPMS than with RRMS stopped IFNβ due to treatment failure (P=0.037). Conclusion: IFNβ discontinuation occurred earlier in the treatment course when due to side effects. Stopping IFNβ therapy was more common in SPMS and was more often due to treatment failure than side effects.

Keywords

beta-interferon multiple sclerosis side effects stopping switching treatment failure

Get full access to this article

View all access options for this article.

References

IFNB Multiple Sclerosis Study Group , the University of British Columbia MS/MRI analysis group . Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial . Neurology 1995; 45: 1277-1285 .

Jacobs LD , Cookfair DL , Rudick RA , Herndon RM , Richert JR , Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis . Ann Neurol 1996; 39: 285-294 .

PRISMS study group . Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis . Lancet 1998; 352: 1498-1504 .

European Study group on interferon beta-1b in secondary progressive MS. Placebo controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis . Lancet 1998; 352: 1491-1497 .

SPECTRIMS study group . Secondary Progressive Efficacy Trial of Recombinant Interferon-beta-1a in MS: randomised controlled trial of interferon beta-1a in secondary progressive MS-clinical results . Neurology 2001; 56: 1496-1504 .

Compston A , Coles A. Multiple sclerosis . Lancet 2002; 359: 1221-1231 .

Neilley LK , Goodin DS , Goodkin DE , Hauser SL. Side effect profile of interferon beta-1b in MS: results of an open label trial . Neurology 1996; 46: 552-554 .

Mohr DC , Goodkin DE , Likosky W , Gatto N , Neilley LK , Griffin C et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: Relationship to adherence to treatment . Mult Scler 1996; 2: 222-226 .

Mohr DC , Likosky W , Boudewyn AC , Marietta P , Dwyer P , Van Der Wende J et al. Side effect profile and adherence in the treatment of multiple sclerosis with interferon beta-1a . Mult Scler 1998; 4: 487-489 .

10.

Milanese C , La Mantia L , Palumbo R , Martinelli V , Murialdo A , Zaffaroni M et al. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients . J Neurol Neurosurg Psychiatry 2003; 74: 1689-1692 .

11.

Tremlett HL , Oger J. Interrupted therapy. Stopping and switching of the beta-interferons prescribed for MS . Neurology 2003; 61: 551-554 .

12.

Poser CM , Paty DW , Scheinberg LC , McDonald WI , Davis FA , Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 1983; 13: 227-231 .

13.

Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-1452 .

14.

Jacobs LD , Beck RW , Simon JH , Kinkel RP , Brownscheidle CM , Murray TJ et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS study group . N Engl J Med 2000; 343: 898-904 .

15.

PRISMS Study Group . PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS . Neurology 2001; 56: 1628-1636 .

16.

Dubois BD , Keenan E , Porter BE , Kapoor R , Rudge P , Thompson AJ et al. Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre . J Neurol Neurosurg Psychiatry 2003; 74: 946-949 .